News and Updates

Tam-Peli reaches a major Phase III milestone for relapsed small-cell lung cancer, potentially offering a new survival-extending option for patients.

Clinical trial results show risvutatug rezetecan significantly boosts overall survival in patients with relapsed small-cell lung cancer. Learn more here.

Trodelvy’s lung cancer trial failed globally but showed promise in China. Explore the implications for this antibody-drug conjugate in modern oncology.

Africa is expanding its clinical trial infrastructure to accelerate Ebola vaccine development, boosting regional research, safety, and global health security.

AstraZeneca’s oral SERD, etcamah, misses primary endpoints in a first-line breast cancer trial, marking another hurdle for the class of targeted therapies.

SeaStar Medical eyes critical growth as it prepares to launch a pivotal clinical trial for its inflammatory-targeting therapy in adult patients.

A key breast cancer treatment faces scrutiny after failing a confirmatory clinical trial shortly after receiving regulatory approval. Read the latest updates.

The FDA has released its 2026 guidance for psychedelic drug trials. Learn how new standards for blinding and patient safety will shape future research.

Explore how a $77 billion investment in AI is reshaping clinical trials, reducing drug development costs, and accelerating the delivery of new treatments.

Explore the 2036 endometriosis market outlook, key pipeline drugs from AbbVie and Organon, and the shifting trends in therapeutic innovation.